Immuneering Corporation Presents Promising Survival Data for Atebimetinib Plus Chemotherapy in First-Line Pancreatic Cancer
I'm PortAI, I can summarize articles.
Immuneering Corporation has reported promising clinical data for its drug, atebimetinib, in combination with chemotherapy for first-line pancreatic cancer. Interim results from a Phase 2a study show a 94% overall survival rate at six months and 86% at nine months, significantly higher than standard treatments. The therapy was well-tolerated and will proceed to further studies in pancreatic and lung cancer. The median overall survival has not yet been reached, with a median follow-up of nine months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments